Gilead Sciences (GILD) Misses Q1 EPS by 5c; Reiterates Full Year 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Bullish Options Activity in Gilead Sciences (GILD) Post Earnings Announcement -Susquehanna
May 3, 2017 2:46 PM EDTSusquehanna options strategists Alison Edwards notes bullish options activity in Gilead Sciences (NASDAQ: GILD), following the company's earnings announcement, as an opening investor bought ~10,000 Dec 70 Calls for $3.30 creating ~400,000 shares to buy.
... MoreGilead Sciences (GILD) PT Raised to $76 at BMO Capital Following 1Q
May 3, 2017 9:17 AM EDTBMO Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $75.00) while maintaining a Market Perform rating. GILD reported 1Q revenues of $6.5bn, below the Street's estimates of $6.62bn, as continued strength from HIV could not off-set further deterioration in HCV.
GILD... More
